Translation of pharmacogenetics into clinically relevant testing modalities

被引:8
作者
Baudhuin, L. M. [1 ]
Langman, L. J. [1 ]
O'Kane, D. J. [1 ]
机构
[1] Mayo Clin, Nucleotide Polymorphism Lab, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
D O I
10.1038/sj.clpt.6100350
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Pharmacogenetics ( PGx) relies on the genetic makeup of an individual to predict drug response and efficacy, as well as potential adverse drug events. Significant advances in PGx research have been made since inherited differences in response to such drugs as isoniazid and succinylcholine were explored in the 1950s,(1,2) and the clinical utility and application of PGx are especially apparent in some subspecialty areas of chemotherapeutic, psychotropic drug, and anticoagulant therapies.
引用
收藏
页码:373 / 376
页数:5
相关论文
共 7 条
[1]
Overview of the pharmacoeconomics of pharmacogenetics [J].
Dervieux, Thierry ;
Bala, Mohan V. .
PHARMACOGENOMICS, 2006, 7 (08) :1175-1184
[2]
GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].
EVANS, DAP ;
MANLEY, KA ;
MCKUSICK, VA .
BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491
[3]
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education [J].
Gurwitz, D ;
Lunshof, JE ;
Dedoussis, G ;
Flordellis, CS ;
Fuhr, U ;
Kirchheiner, J ;
Licinio, J ;
Llerena, A ;
Manolopoulos, V ;
Sheffield, LJ ;
Siest, G ;
Torricelli, F ;
Vasiliou, V ;
Wong, S .
PHARMACOGENOMICS JOURNAL, 2005, 5 (04) :221-225
[4]
KALOW W, 1956, LANCET, V271, P576
[5]
McWilliam A., 2006, HLTH CARE SAVINGS PE
[6]
Individualizing warfarin therapy [J].
Reynolds, Kristen K. ;
Valdes, Roland, Jr. ;
Hartung, Bronwyn R. ;
Linder, Mark W. .
PERSONALIZED MEDICINE, 2007, 4 (01) :11-31
[7]
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients:: A HuGEnet™ systematic review and meta-analysis [J].
Sanderson, S ;
Emery, J ;
Higgins, J .
GENETICS IN MEDICINE, 2005, 7 (02) :97-104